WuXi XDC Announces the Mechanical Completion of its Singapore Site, Accelerating the Global Expansion of Bioconjugates Manufacturing
As a critical component of WuXi XDC's global strategy, the Singapore site has demonstrated exceptional progress, adhering to the perfect execution and the 'WuXi Speed' to provide customers with agile and flexible end-to-end CRDMO services. According to current capacity plan, the site is anticipated to create more than 500 job opportunities and over 100 people have joined our company so far.
Dr. Jimmy Li, CEO of WuXi XDC, stated, " The rapid mechanical completion of our Singapore site marks a critical pillar in our 'Global Dual-Sourcing' strategy. This global site will form a worldwide network alongside our Wuxi, Changzhou, and Shanghai sites, delivering end-to-end CRDMO services to global customers. This accomplishment showcases the full support of the partners for the construction of Singapore site, our deep understanding of global market demands, our ability to respond swiftly and the robust execution capabilities of our team. Looking ahead, we remain committed to advancing our one-stop model and global supply network, collaborating with global partners to promote the diversified and sustainable development of bioconjugates.'
The Singapore site serves as a world-class, one-stop bioconjugates manufacturing center, integrating antibody intermediates, drug substance (DS), and drug products (DP). It strictly adheres to international certification standards and utilizes an advanced modular factory design. Key features include state-of-the-art antibody intermediates production lines, bioconjugate DS and DP production lines, MSAT lab, quality control, intelligent warehousing, and other utility support areas. Equipped with cutting-edge isolator filling lines, fully automated material transfer systems, and digital production management systems, the Singapore site supports multi-level demands ranging from small-scale clinical supplies to large-scale commercial manufacturing, including up to 2,000 liters per batch of mAb/DS, and 8 million vials of DP per year. These capabilities ensure the efficient advancement of projects across various stages while maintaining adherence to the highest quality standards.
The Singapore site will be operated under the highest international quality assurance standards, fully complying with Good Manufacturing Practice (GMP) regulations established by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and China's National Medical Products Administration (NMPA). This ensures comprehensive compliance throughout the production process, from antibody intermediates and DS to DP, enabling seamless product release globally. Additionally, the site incorporates environmentally friendly practices, utilizing certified eco-friendly products and implementing strict recycling and waste disposal systems to promote sustainability and enhance the company's ESG management level.
About WuXi XDC
WuXi XDC Cayman Inc. (stock code: 2268.HK) is a globally recognized contract research, development, and manufacturing organization (CRDMO) specializing in bioconjugates. The company offers a wide range of innovative conjugation and payload-linker technologies to facilitate the development of next-generation antibody-drug conjugates (ADCs). Focused on early-stage research and development of ADCs and other bioconjugates, WuXi XDC offers comprehensive one-stop services from clinical to commercial manufacturing. Its services cover antibody intermediates and other biologics intermediates, chemical payloads and linkers, as well as bioconjugate drug substances and drug products. For more information about WuXi XDC, please visit: www.wuxixdc.com
WuXi XDC Contacts
Investor: [email protected]
Media: [email protected]
BD: [email protected]
View original content: https://www.prnewswire.com/news-releases/wuxi-xdc-announces-the-mechanical-completion-of-its-singapore-site-accelerating-the-global-expansion-of-bioconjugates-manufacturing-302495535.html
SOURCE WuXi XDC
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
TechCrunch
2 hours ago
- TechCrunch
Amazon deploys its 1 millionth robot, releases generative AI model
After 13 years of deploying robots into its warehouses, Amazon reached a new milestone. The tech behemoth now has 1 million robots in its warehouses, the company announced Monday. This one millionth robot was recently delivered to an Amazon fulfillment facility in Japan. That figure puts Amazon on track to reach another landmark: Its vast network of warehouses may soon have the same number of robots working as people, according to reporting from The Wall Street Journal. The WSJ also reported that 75% of Amazon's global deliveries are now assisted in some way by a robot. TechCrunch reached out to Amazon for more information. The company also announced it's releasing a new generative AI model called DeepFleet for its warehouse robots. This AI model, which can coordinate the robots' routes within the company's warehouses more efficiently, will help increase the speed of its robotic fleet by 10%, according to Amazon. The company used Amazon SageMaker — the AWS cloud studio that helps build and deploy AI models — to create DeepFleet. Amazon trained the model on its own warehouse and inventory data. Amazon's one millionth robot represents more than just a number. The company has improved its fleet of robots in recent years, adding new capabilities and models. Techcrunch event Save $450 on your TechCrunch All Stage pass Build smarter. Scale faster. Connect deeper. Join visionaries from Precursor Ventures, NEA, Index Ventures, Underscore VC, and beyond for a day packed with strategies, workshops, and meaningful connections. Save $200+ on your TechCrunch All Stage pass Build smarter. Scale faster. Connect deeper. Join visionaries from Precursor Ventures, NEA, Index Ventures, Underscore VC, and beyond for a day packed with strategies, workshops, and meaningful connections. Boston, MA | REGISTER NOW In May, the company unveiled its latest robot, Vulcan. This model has two arms, one designed for rearranging inventory and another with a camera and suction cup to grab items. Most notably, these Vulcan robots have a sense of 'touch' that allows it to feel the items it is grabbing, according to Amazon. In October 2024, the company announced its 'next-generation fulfillment centers,' which would include 10x as many robots as their current facilities, in addition to human workers. The first of these new robotic-powered centers opened shortly after in Shreveport, Louisiana, near the Texas border. Amazon originally started building up its robotic capabilities back in 2012 alongside its acquisition of Kiva Systems.
Los Angeles Times
2 hours ago
- Los Angeles Times
Hollywood's Sigma Girl Inks AI Content Pact with Singaporean Animation Shop Tiny Island
Los Angeles-based Sigma Girl Media has announced its strategic partnership with Tiny Island Productions, a Singapore-based leader in AI-driven animation. This collaboration leverages Tiny Island's cutting-edge AI pipeline and experienced animators to create custom short-form content delivered faster and more affordably than traditional animation, empowering brands and IP owners to meet growing demand for fresh, engaging content across multiple platforms. Sigma Girl Media and Tiny Island Productions aim to set a new industry benchmark by harnessing generative AI to help brands rapidly create stories and campaigns, delivering content up to 10 times faster and at 50% lower costs than conventional animation studios. Helmed by industry veteran Amy Takahara, Sigma Girl Media leads business development efforts with a focus on seamless collaboration and measurable impact for clients worldwide. Beyond content production, the partnership delivers end-to-end creative development and production services, taking projects from concept through execution. Takahara brings more than six years of experience at Netflix, where she most recently served as director of kids & family acquisitions and co-commissions, overseeing strategy across animation and live action. Prior to Netflix, she was director of global acquisitions at Nickelodeon and earlier held key distribution roles at The Jim Henson Company, Mattel and Fremantle. This breadth of experience has cemented Takahara's reputation as a respected and influential leader in the global entertainment industry. Beyond AI solutions, Tiny Island Productions brings strong business relationships in China and across Asia, offering valuable insights into emerging trends, such as micro-dramas. As this format grows in popularity, the partnership uses AI to help brands leverage this trend, creating micro-dramas or elevating production values with AI-generated VFX at a fraction of the traditional cost. Tiny Island's deep industry connections and knowledge of regional markets allow brands to effectively navigate and capitalize on these opportunities in the fast-growing Asian market. 'With Amy's two decades of Hollywood insight, this partnership is a game-changer,' said Tiny Island CEO David Kwok. 'Our focus? Revolutionizing micro-drama through AI – merging creativity and technology to redefine entertainment.' Tiny Island Productions is committed to keeping its creative talents on the cutting edge of technology. Through rigorous training, the studio ensures that its talents are equipped to produce AI-generated content, creating a future where talent and innovation go hand in hand. This dedication to both technology and people guarantees high-quality content, while keeping creatives employed and empowered in the evolving digital entertainment landscape. Currently, Tiny Island is partnering with ITE to launch a SkillsFuture Industry Training Program where up to 90% of the training fee is covered by this fund. 'I'm incredibly excited to be partnering with Tiny Island Productions on this groundbreaking AI initiative,' said Takahara. 'As a leading animation studio, they bring not only deep expertise but also a forward-thinking approach to integrating AI into the creative process. What's especially inspiring is their commitment to training and empowering their animators to create AI-assisted content, ensuring that people remain at the heart of innovation. Together, we're setting the stage for a new era of high-quality, human-driven storytelling enhanced by AI.' Information was sourced from Sigma Girl. To learn more, contact amy@ or davidk@
Entrepreneur
2 hours ago
- Entrepreneur
How One Founder Is Rethinking Supplements With David Beckham
5 lessons on how to bring trust and transparency into a controversial industry. Opinions expressed by Entrepreneur contributors are their own. When Danny Yeung sat down for dinner with soccer legend David Beckham, there was no agenda. No pitch deck. Just two guys talking health. They met through a mutual friend in Hong Kong. Yeung, the CEO of Prenetics, a health tech company specializing in genomics and diagnostics, wanted to create a wellness brand rooted in science. Beckham wanted a product he could take every day without juggling a shelf full of pills. That conversation led to the creation of IM8, a supplement powder designed to support energy, gut health, immunity, and focus. In five months, it has shipped more than 3 million servings to customers in 31 countries. The growth has been sizeable. In its first full quarter of sales, IM8 generated $5.7 million in revenue, helping Prenetics raise its full-year forecast to between $80 and $100 million. Beckham's endorsement helped, of course. But Yeung says the goal wasn't just to put a famous face on the box. It was to create something the founder and the athlete would both want to use. Beckham takes the product daily. His kids take it. His parents do, too. "If this product didn't work, David wouldn't use it—and neither would I," Yeung says. "We built it for ourselves first. Everything else came after." Here's what Yeung learned in building the company. Lesson 1: Start with science Yeung says the vast majority of supplement companies work backward—designing the brand first and then sourcing ingredients to fit a specific price point. "They lead with a logo and build the formula later," he says. "That's not how it should work." IM8 reversed the process. Before a single package was designed, the company spent over a year developing the formula with scientists and doctors, many of whom had never partnered with a supplement brand before. "We approached it like a biotech company," Yeung says. "We had real clinical trials, real data. No fluff." Related: The Supplement Business Has a Trust Problem. This Tech Startup Wants to Fix That. Lesson 2: Transparency isn't optional With more than 200,000 supplements on the market and little federal oversight, many consumers are understandably skeptical. "You can sell dust and call it protein. That's legal. That's the reality," says Yeung. IM8 tries to counter that with full transparency. The formula includes over 90 ingredients, including CoQ10, prebiotics, probiotics, and postbiotics. It's NSF Certified for Sport. Lab test results are published online. And the company publicly names its manufacturing partner. Lesson 3: Keep it simple Beckham wanted fewer pills in his daily routine. The idea behind IM8's Daily Ultimate Essentials was to simplify supplementation: one scoop, once a day, covering multiple health needs. The brand has plans to expand, but only with a few highly vetted products per year. Yeung emphasizes quality over speed. "We're not a company that wants to launch 50 different products. We want to focus on doing a few things very well. If we don't think something is best in class, we won't do it." Yeung's taking that same mindset to the business side. Prenetics is in active discussions with crypto industry veterans to integrate Bitcoin into its treasury strategy. Related: Inside The New Era of Longevity Supplements Lesson 4: A celebrity partner can't fix a bad product Yeung says too many founders look for celebrity partners to grab attention, not to build staying power. "I didn't want to be just another celebrity brand. We've seen too many of those," he says. That's why he didn't pitch Beckham on a business. They met over dinner. Talked science. Swapped health routines. "It wasn't a transaction," Yeung says. "It was two people figuring out if they believed in the same thing." Yeung believes Beckham didn't just join because of a business opportunity, but because he believed in the science. He has been involved in the process, reviewing product iterations, offering feedback on packaging, and flagging early customer reactions. Lesson 5: Trust has to be earned You can put a famous face on your brand, but if it doesn't work, you're not going to last. "People know when something's real," he says. "You can't fake that." Yeung calls IM8 a "trust product." Customers are putting it in their bodies every day, and that responsibility shapes how the business operates. The brand's 12-week clinical study showed that 95% of participants reported feeling more energized. Customer retention is strong. And feedback, Yeung says, has been more meaningful than any marketing metric. "If people are putting this in their bodies every day, you better get it right." Related: Trust Is a Business Metric Now. Here's How Leaders Can Earn It.
